Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Deutsches Krebsforschungszentrum

Jeffrey Stuart Mowat

Bernd Buchmann

Roland Neuhaus

Thomas Brumby

Olaf Panknin

Clara Christ

Kirstin Petersen

Detlef Stöckigt

Timo Stellfeld

Sandra Berndt

Antonius Ter Laak

Roman Hillig

Naomi Barak

Rafael Carretero

Rienk Offringa

Jörg Weiske

Volker Badock

Carlo Stresemann

Silke Köhr

Rosemary Helen Crampton

Ian Stefanuti

Nuria Aiguabella Font

Gabriele Leder

Robin Michael Meier

Naomi Barack

The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R, R, R, R, R, Rand Rare as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control. 

Substituted pyrrolopyridine-derivatives

The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R, R, R, R, R, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility. 

Aryl-cyanoguanidine compounds

Growing community of inventors

Berlin, Germany

Jeffrey Stuart Mowat